Pre-eclampsia screening should use the FMF algorithm, not risk factors alone
(AJGP, Oct 2026). RANZCOG recommends offering every woman first-trimester screening;
the Fetal Medicine Foundation algorithm (MAP, uterine artery PI, PlGF/PAPP-A at 11–14
weeks) detects about 82% of preterm pre-eclampsia versus 30–40% for risk factors. Risk
above 1 in 100 means aspirin, ideally 150 mg at night from before 16 weeks. See
Pre-eclampsia/hypertension in pregnancy.
Cancer screening for trans and gender-diverse people goes by anatomy (AJGP, Oct 2026):
cervical screening for anyone with a cervix; breast screening for trans women at 50–74
after 5 years of GAHT in most states. See Cervical Screening
and Breast Cancer & Screening.
PCOS has been renamed PMOS (polyendocrine metabolic ovarian syndrome) as of May
2026, via a global consensus process published in The Lancet. The diagnostic
criteria and management are explicitly unchanged — only the name changes. See
PCOS (now PMOS).
Anti-D/Rh D testing is no longer routinely recommended before 10 weeks’ for
threatened miscarriage/miscarriage, and recurrent miscarriage is now defined as 2+
losses (was 3, ESHRE 2022). Septum resection for recurrent pregnancy loss is now
explicitly not recommended. See Miscarriage
and Recurrent Miscarriage (RANZCOG C-Gyn 38,
March 2025).
Mastitis management has reversed. The old advice to increase feeding/pumping on
the affected breast is now considered counterproductive (drives hyperlactation) —
milk stasis doesn’t cause mastitis. Reframed as a spectrum (bleb, galactocele,
phlegmon, inflammatory/bacterial/recurrent mastitis, abscess) per the ABM 2022
protocol. See Mastitis.
Contraception: Mirena’s licence extended from 5 to 8 years (FSRH Jan 2024);
LNG-IUD/implant/DMPA are now first-line progestogen options for heavy menstrual
bleeding/endometriosis regardless of contraceptive need; emergency contraception
moved to a single 1.5mg LNG dose, replacing the old split-dose regimen. See
Progestogen-Only & LARC and
Emergency Contraception.
Cervical screening: Test of Cure after HSIL is now HPV-only (not co-testing), and
AIS surveillance is no longer indefinite (now 5yr annual then 3-yearly with a 25yr
exit). Self-collection expanded to universal eligibility (ages 25–74) from July 2022.
See Cervical Screening.
Endometriosis: long-acting progestogens now first-line (not just short-term oral
progestogens), dienogest added, GnRH-agonist add-back now extends use to 2 years. See
Endometriosis.
Fibroids: UAE outcome/complication data now specific (~35% eventual hysterectomy
at 10 years) with an explicit fertility caution against routine UAE. See
Uterine Fibroids.
Chlamydia treatment reversed to doxycycline-first-line (Aus STI guidelines
2023–24); HPV vaccination now single-dose Gardasil 9 (Feb 2023); maternal RSV
vaccine (Abrysvo, TGA March 2024, NIP-funded from Feb 2025, 28–36 weeks) added to
Routine Antenatal Care;
romosozumab PBS-expanded to first-line severe osteoporosis.
Mammographic density notification is now national policy: BreastScreen Australia’s
November 2024 position statement (v2.0) requires women be informed IN WRITING of their
breast density. The November 2025 Breast Density GP Guidance then supplies the actual
GP pathway — screening interval and supplemental imaging (MRI/CEM, ultrasound, DBT)
stratified by density category and RACGP family-history risk category, not density
alone. See Breast Cancer & Screening.
Routine antenatal care rewritten around the first-trimester GP workflow: universal
14-week specialist referral regardless of risk tier, corrected folic acid dosing,
routine vitamin D, reproductive carrier screening, fetal RhD NIPT, and the Safer
Baby Bundle stillbirth-prevention framework — none of which were in the 2020
original. See Routine Antenatal Care.
New pages added
Medical Abortion — MS-2 Step; TGA
deregulation (July 2023) noted.